Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection

References

• Deutscher S. L., Harley J. B., Keene J. D.. Molecular analysis of the 60-kDa human Ro ribonucleoprotein. Proc. Natl. Acad. Sci. USA. 1988; 85:9479–9483.
   PubMed Web of Science ®Google Scholar
• Ben Chetrit E., Gandy B. J., Tan E. M., Sullivan K. F.. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J. Clin. Invest.. 1989; 83:1284–1292.
   PubMed Web of Science ®Google Scholar
• Chan E. K., Hamel J. C., Buyon J. P., Tan E. M.. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J. Clin. Invest.. 1991; 87:68–76.
   PubMed Web of Science ®Google Scholar
• Fuchs G., Stein A. J., Fu C., Reinisch K. M., Wolin S. L.. Structural and biochemical basis for misfolded RNA recognition by the Ro autoantigen. Nat. Struct. Mol. Biol.. 2006; 13:1002–1009.
   PubMed Web of Science ®Google Scholar
• Wada K., Kamitani T.. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem. Biophys. Res. Commun.. 2006; 339:415–421.
   PubMed Web of Science ®Google Scholar
• Kelakar A., Saitta M. R., Keene J. D.. Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins. J. Clin. Invest.. 1994; 93:1637–1644.
   PubMed Web of Science ®Google Scholar
• Yell J. A., Wang L., Yin H., McCauliffe D. P.. Disparate locations of the 52- and 60-kDa Ro/SS-A antigens in cultured human keratinocytes. J. Invest. Dermatol.. 1996; 107:622–626.
   PubMed Web of Science ®Google Scholar
• Slobbe R. L., Pruijn G. J., Damen W. G. M., Van der Kamp J. W. C. M., Van Venrooij W. J.. Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. Clin. Exp. Immunol.. 1991; 86:99–105.
   PubMed Web of Science ®Google Scholar
• López-Longo F. J., Rodríguez-Mahou M., Escalona M., . Heterogeneity of the anti-Ro(SSA) response in rheumatic diseases. J. Rheumatol.. 1994; 21:1450–1456.
   PubMed Web of Science ®Google Scholar
• Peene I., Meheus L., Veys E. M., De Keyser F.. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann. Rheum. Dis.. 2002; 61:1090–1094.
   PubMed Web of Science ®Google Scholar
• Bahon-Riedinger I.. Auto-antibodies to ENA SSA/Ro (52 and 60 kD): an autoimmunity laboratory's experience. Rev. Med. Intern.. 2004; 25:421–428.
   PubMed Web of Science ®Google Scholar
• Dugar M., Cox S., Limaye V., Gordon T. P., Roberts-Thomson P. J.. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad. Med. J.. 2010; 86:79–82.
   PubMed Web of Science ®Google Scholar
• Francheschini F., Cavazzana I.. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity. 2005; 38:55–63.
   PubMed Web of Science ®Google Scholar
• Keech C. L., Gordon T. P., McCluskey J.. The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J. Immunol.. 1996; 157:3694–3699.
   PubMed Web of Science ®Google Scholar
• Tseng Ch. -E., Chan E. K. L., Miranda E., . The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. Arthritis Rheum.. 1997; 40:936–944.
   PubMedGoogle Scholar
• Itoh I., Itoh K., Frank M. B., Reichlin M.. Autoantibodies to the Ro/SSA autoantigen are conformational dependent. II. Antibodies to the denatured form of 52 kD Ro/SSA are a cross-reacting subset of antibodies to the native 60 kD Ro/SSA molecule. Autoimmunity. 1992; 14:89–95.
   PubMed Web of Science ®Google Scholar
• Kurien B. T., Chambers T. L., Thomas P. Y., Frank M. B., Scofield R. H.. Autoantibody to the leucine-zipper region of 52 kDa Ro/SSA binds native 60 kDa Ro/SSA: Identification of a tertiary epitope with components from 60 kDa Ro/SSA and 52 kDa Ro/SSA. Scand. J. Immunol.. 2001; 53:268–276.
   PubMed Web of Science ®Google Scholar
• St Clair E. W., Burch J. A., Saitta M.. Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. Arthritis Rheum.. 1994; 9:1373–1379.
   Google Scholar
• Boire G., Gendron M., Monast M., Ménard H. A.. Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD is not a Ro protein. Clin. Exp. Immunol.. 1995; 100:489–498.
   PubMed Web of Science ®Google Scholar
• Buyon J. P., Winchester R. J., Slade S. G., . Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum.. 1993; 36:1263–1273.
   PubMed Web of Science ®Google Scholar
• Fritsch C., Hoebeke J., Dali H., . 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res. Ther.. 2006; 8:R4.
   PubMed Web of Science ®Google Scholar
• Rutjes S. A., Vree Egberts W. T., Jongen P., . Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin. Exp. Immunol.. 1997; 109:32–40.
   PubMed Web of Science ®Google Scholar
• Frank M. B., McCubbin V., Trieu E., . The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J. Autoimmun.. 1999; 12:137–142.
   PubMed Web of Science ®Google Scholar
• Brouwer R., Hengstman G. J. D., Vree Egberts W., . Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis.. 2001; 60:116–123.
   PubMed Web of Science ®Google Scholar
• Koenig M., Fritzler M. J., Targoff I. N., Troyanov Y., Senécal J. L.. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res. Ther.. 2007; 9:R78.
   PubMed Web of Science ®Google Scholar
• Parker J. C., Burlingame R. W., Bunn C. C.. Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J. Autoimmun. Dis.. 2009; 6:2.
   PubMedGoogle Scholar
• Schulte-Pelkum J., Fritzler M., Mahler M.. Latest update on the Ro/SS-A autoantibody system. Autoimmun. Rev.. 2009; 8:632–637.
   PubMed Web of Science ®Google Scholar
• Ghillani P., André C., Toly C., . Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: Results of a multicentric study. Autoimmun. Rev.. 2011; 10:509–513.
   PubMed Web of Science ®Google Scholar
• Hudson M., Pope J., Mahler M., . Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res. Ther.. 2012; 14:R50.
   PubMed Web of Science ®Google Scholar
• Sontheimer R. D.. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun. Rev.. 2005; 4:253–263.
   PubMed Web of Science ®Google Scholar
• Lee L. A., Roberts C. M., Frank M. B., McCubbin V. R., Reichlin M.. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch. Dermatol.. 1994; 130:1262–1268.
   PubMedGoogle Scholar
• Granito A., Muratori P., Muratori L., . Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol. Ther.. 2007; 26:831–838.
   PubMed Web of Science ®Google Scholar
• Czaja A. J., Nishioka M., Morshed S. A., Hachiya T.. Patterns of nuclear fluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994; 107:200–207.
   PubMed Web of Science ®Google Scholar
• Liaskos C., Bogdanos D. P., Rigopoulo E. I., . Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis. J. Hepatol. Suppl.. 2009; 1:250.
   Google Scholar
• Hervier B., Rimbert M., Colonna F., Hamidou M. A., Audrain M.. Clinical significance of anti-Ro/SSA-52 kDa antibodies—a retrospective monocentric study. Rheumatology. 2009; 48:964–967.
   PubMed Web of Science ®Google Scholar
• Hochberg M. C.. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.. 1997; 40:1725.
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Jonsson R., . European Study Group on Classification Criteria for Sjögren's syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis.. 2002; 61:554–558.
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.. 1988; 31:315–324.
   PubMed Web of Science ®Google Scholar
• Lonzetti L. S., Joyal F., Raynauld J. P., . Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum.. 2001; 44:735–736.
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D., Cardiel M. H.. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol.. 1989; 16:328–334.
   PubMed Web of Science ®Google Scholar
• Miyakis S., Lockshin M. D., Atsumi T., . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.. 2006; 4:295–306.
   PubMed Web of Science ®Google Scholar
• Targoff I. N., Miller F. W., Medsger T. A.Jr., Oddis C. V.. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol.. 1997; 9:527–535.
   PubMedGoogle Scholar
• Kapplan M. M., Gershwin M. E.. Primary billiary cirrhosis. N. Engl. J. Med.. 2005; 353:1261–1273.
   PubMedGoogle Scholar
• Alvarez F., Berg P., Bianchi F., . International Autoimmune Hepatitis Group Report. Review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol.. 1999; 31:929–938.
   PubMed Web of Science ®Google Scholar
• Gál I., Lakos G., Zeher M.. Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjögren's syndrome. Autoimmunity. 2000; 32:89–92.
   PubMed Web of Science ®Google Scholar
• Xue D., Shi H., Smith J. D., . A lupus-like syndrome develops in mice lacking the Ro60-kDa protein, a major lupus autoantigen. Proc. Natl. Acad. Sci. USA. 2003; 100:7503–7508.
   PubMed Web of Science ®Google Scholar
• Heinlen L. D., McClain M. T., Ritterhouse L. L., . 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLosOne. 2010; 5:e9599.
   PubMed Web of Science ®Google Scholar
• Cavazzana I., Franceschini N., Belfiore N., . Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients. Clin. Exp. Immunol.. 2001; 19:403–409.
   Google Scholar
• Belfiore N., Rossi S., Bobbio-Pallavicini F., . Anti-Ro(SS-A) 52 kDa and 60 kDa specificities in undifferentiated connective tissue disease. Joint Bone Spine. 2006; 67:183–187.
   Google Scholar
• Popovic K., Brauner S., Ek M., Wahren-Herlenius M., Nyberg F.. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus. 2007; 16:10–17.
   PubMed Web of Science ®Google Scholar
• Peene I., Meheus L., De Keyser S., . Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann. Rheum. Dis.. 2002; 61:929–933.
   PubMed Web of Science ®Google Scholar
• Langguth D. M., Morris S., Clifford L., . Specific testing for “isolated” anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen is of limited clinical value. J. Clin. Pathol.. 2007; 60:670–673.
   PubMed Web of Science ®Google Scholar
• Montano-Loza A. J., Shums Z., Norman G. L., Czaja A. J.. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int.. 2012; 32:85–92.
   PubMed Web of Science ®Google Scholar
• La Corte R., Lo Monaco A., Locaputo A., Dolzani F., Trotta F.. In patients with anti-synthetase síndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006; 39:249–253.
   PubMed Web of Science ®Google Scholar
• Gogas H., Ioannovich J., Dafni U., . Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.. 2006; 354:709–718.
   PubMed Web of Science ®Google Scholar
• Burbelo P. D., Ching K. H., Han B. L., . Extraordinary antigenicity of the human Ro52 autoantigen. Am. J. Transl. Res.. 2010; 2:145–155.
   PubMed Web of Science ®Google Scholar
• Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A.. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett.. 2009; 281:8–23.
   PubMed Web of Science ®Google Scholar